3 Promising Penny Stocks With Market Caps Over $70M

With the recent surge in U.S. stock markets following the Federal Reserve's interest rate cuts, investors are keenly observing how these changes might impact various sectors. While major indices like the S&P 500 and Dow Jones have shown significant gains, there remains a growing interest in exploring opportunities beyond traditional blue-chip stocks. Penny stocks, often associated with smaller or newer companies, continue to capture attention due to their affordability and potential for growth when backed by strong financials. In this article, we explore several penny stocks that stand out for their financial strength and potential long-term value amidst current market conditions.

Top 10 Penny Stocks In The United States

Name Share Price Market Cap Financial Health Rating Dingdong (Cayman) (DDL) $2.10 $435.04M ★★★★★★ Waterdrop (WDH) $1.75 $614.83M ★★★★★☆ WM Technology (MAPS) $0.8895 $151.06M ★★★★★★ LexinFintech Holdings (LX) $3.235 $545.17M ★★★★★★ Tuya (TUYA) $2.28 $1.39B ★★★★★★ CI&T (CINT) $4.52 $588.07M ★★★★★☆ Golden Growers Cooperative (GGRO.U) $5.00 $77.45M ★★★★★★ VAALCO Energy (EGY) $3.54 $369.07M ★★★★☆☆ BAB (BABB) $0.8886 $6.25M ★★★★★★ Lifetime Brands (LCUT) $4.42 $104.67M ★★★★★☆

Click here to see the full list of 342 stocks from our US Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Siebert Financial

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Siebert Financial Corp., with a market cap of $133.41 million, operates in the United States providing brokerage and financial advisory services through its subsidiaries.

Operations: The company generates revenue of $90.29 million from its operations in the securities brokerage and asset management industry.

Market Cap: $133.41M

Siebert Financial Corp. is navigating the penny stock landscape with a market cap of US$133.41 million and revenues of US$90.29 million, yet faces challenges such as declining net profit margins from 12.9% to 8.1% over the past year and negative earnings growth (-31.9%). Despite these hurdles, Siebert's strategic initiatives like launching Siebert.Pro for self-directed investors and partnering with Academy Asset Management highlight its focus on innovation and expansion in niche markets. The company's short-term assets comfortably cover both its short- and long-term liabilities, providing some financial stability amidst its evolving business strategy.

Click here and access our complete financial health analysis report to understand the dynamics of Siebert Financial. Gain insights into Siebert Financial's past trends and performance with our report on the company's historical track record.

Story continues

SIEB Debt to Equity History and Analysis as at Dec 2025

Acrivon Therapeutics

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oncology medicines tailored to patients' tumor profiles using its generative phosphoproteomics platform, with a market cap of $78.57 million.

Operations: Currently, there are no reported revenue segments for this clinical-stage biopharmaceutical entity.

Market Cap: $78.57M

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical firm with a market cap of US$78.57 million, operates without generating significant revenue and remains pre-revenue. Despite being debt-free and having short-term assets of US$130.4 million that exceed its liabilities, the company faces challenges such as unprofitability with net losses reported at US$18.23 million for Q3 2025. Although Acrivon has an experienced management team and board, its earnings are forecast to decline by 10.6% annually over the next three years, highlighting the inherent volatility and risk associated with investing in penny stocks like Acrivon in the biotech sector.

Jump into the full analysis health report here for a deeper understanding of Acrivon Therapeutics. Gain insights into Acrivon Therapeutics' outlook and expected performance with our report on the company's earnings estimates.ACRV Debt to Equity History and Analysis as at Dec 2025

Autolus Therapeutics

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Autolus Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing T cell therapies for cancer and autoimmune diseases, with a market cap of approximately $396.55 million.

Operations: The company generates $51.13 million in revenue from developing and commercializing CAR-T therapies.

Market Cap: $396.55M

Autolus Therapeutics, with a market cap of US$396.55 million, is a clinical-stage biopharmaceutical company focused on CAR-T therapies. It reported US$51.13 million in revenue for the first nine months of 2025 but remains unprofitable with net losses widening over five years. Recent developments include FDA approval for AUCATZYL and positive trial data presented at the ASH Annual Meeting, suggesting potential long-term benefits for patients with r/r B-ALL. While its short-term assets exceed liabilities and no significant shareholder dilution occurred recently, high volatility and increasing debt-to-equity ratio underscore the risks typical of penny stocks in biotech.

Dive into the specifics of Autolus Therapeutics here with our thorough balance sheet health report. Gain insights into Autolus Therapeutics' future direction by reviewing our growth report.AUTL Debt to Equity History and Analysis as at Dec 2025

Where To Now?

Dive into all 342 of the US Penny Stocks we have identified here. Contemplating Other Strategies? The end of cancer? These 29 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SIEBACRV and AUTL.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View comments